SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that it is advancing its clinical program to support the submission of the company’s PLAC® Test for Lp-PLA2 Activity. This important next step in the regulatory clearance process follows a recent pre-submission meeting with the U.S. Food and Drug Administration (FDA).
Help employers find you! Check out all the jobs and post your resume.
